Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/STROKEAHA.107.486969 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
Cochrane Database Syst Rev
April 2023
Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada.
Article Synopsis
- Deep vein thrombosis (DVT) is a condition where a clot forms in the deep veins, usually in the leg, and if untreated, can lead to a dangerous pulmonary embolism (PE).
- The introduction of direct oral anticoagulants (DOACs), including oral direct thrombin inhibitors and oral factor Xa inhibitors, offers benefits over traditional treatments such as ease of use, predictable effects, and fewer drug interactions.
- This Cochrane Review aims to update the effectiveness and safety of DOACs compared to conventional anticoagulants for the long-term treatment of DVT, using data from various health databases and including only randomized controlled trials (RCTs) in the analysis.
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Cochrane Database Syst Rev
June 2018
Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Background: Cancer increases the risk of thromboembolic events, especially in people receiving anticoagulation treatments.
Objectives: To compare the efficacy and safety of low molecular weight heparins (LMWHs), direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) for the long-term treatment of venous thromboembolism (VTE) in people with cancer.
Search Methods: We conducted a literature search including a major electronic search of the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 1), MEDLINE (Ovid), and Embase (Ovid); handsearching conference proceedings; checking references of included studies; use of the 'related citation' feature in PubMed and a search for ongoing studies in trial registries.
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
J Cardiol
December 2015
Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus School of Medicine, Okinawa, Japan. Electronic address:
Background: This study was designed to compare efficacy and safety among novel oral anticoagulants (NOACs), which have not been directly compared in randomized control trials to date.
Method: We performed network meta-analyses of randomized control trials in preventing thromboembolic events and major bleeding in patients with atrial fibrillation. PubMed, Embase, and the Cochrane Database of Systematic Reviews for published studies and various registries of clinical trials for unpublished studies were searched for 2002-2013.
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Cochrane Database Syst Rev
July 2014
Department of Internal Medicine, American University of Beirut, Riad El Solh St, Beirut, Lebanon.
Background: Cancer increases the risk of thromboembolic events in patients including those receiving anticoagulation treatments.
Objectives: To compare the efficacy and safety of low molecular weight heparin (LMWH) and oral anticoagulants for the long-term treatment of venous thromboembolism (VTE) in patients with cancer.
Search Methods: We conducted a comprehensive search for studies of anticoagulation in cancer patients including 1.
Direct oral anticoagulants (DOACs) versus "new" oral anticoagulants (NOACs)?
Semin Hematol
April 2014
Unilabs Coagulation Laboratory and Center for Perioperative Thrombosis and Hemostasis Zurich, Switzerland. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!